Compounded tirzepatide, prescribed online — bilingual.

No. Zepbound® is the FDA-approved finished tirzepatide product manufactured by Eli Lilly. REMEVi prescribes compounded tirzepatide, a non-FDA-approved preparation made by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. Compounded tirzepatide is a preparation containing the peptide tirzepatide; it is not a generic of Zepbound® and has not been clinically studied as a finished product. Your licensed provider reviews the risks, benefits, and considerations of compounded medication with you before prescribing.

Most patients consider a Zepbound alternative for one of three reasons: (1) Zepbound® costs roughly $1,000–$1,400 per month without insurance and many plans deny weight-loss prior authorizations; (2) Zepbound has been on FDA shortage lists, making fills inconsistent at the pharmacy counter; (3) patients in the Hispanic community often want bilingual care that brand-channel clinics can't provide. REMEVi compounded tirzepatide is prescribed by US licensed providers, prepared at state-licensed compounding pharmacies, and starts at $249 for your first month ($130 welcome discount applied automatically at checkout), then $379/month — or as low as $269/month on the 52-week plan.

Compounded tirzepatide at REMEVi is all-inclusive: $249 for your first month ($130 welcome discount applied automatically at checkout), then $379/month — or $339/mo on the 12-week plan and $269/mo on the 52-week plan (Best Value). Every plan covers the licensed clinical evaluation, the medication itself, syringes and supplies, monthly free shipping, and a bilingual care coordinator. No lab fees, no consult fees, no surprise renewal charges.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it works through two receptor pathways instead of one. Branded Zepbound® uses the same molecule. In the SURMOUNT-1 trial of the FDA-approved branded product, patients lost an average of 22.5% of body weight at 72 weeks at the highest dose. Those trial results describe Zepbound, not compounded preparations, which have not been clinically studied as finished products. Your licensed provider helps decide which option fits your medical history.

Yes. REMEVi is LegitScript certified (validation ID 50384507), the gold-standard third-party legitimacy program recognized by Google, Meta, and the major ad networks. Every prescription is reviewed by a US board-certified licensed provider credentialed via OpenLoop's NCQA-accredited credentialing program. Medications ship from FDA-registered 503A or 503B compounding pharmacies. The intake takes about 5 minutes and the licensed clinical review typically happens within 24 hours.

Yes — REMEVi is the only US telehealth platform built natively bilingual from day one. Intake, clinical evaluation, dosing instructions, patient portal, billing, and care coordinator communications are all available in Spanish. Care coordinators are native Spanish speakers, not translators. You can switch languages at any point in the portal without losing your history. Visit /es/alternativa-zepbound/ for the Spanish version of this page.

No. There is no over-the-counter version of Zepbound® or of tirzepatide, and any product sold OTC as a "Zepbound alternative" is not tirzepatide. Tirzepatide is a prescription-only medication in the United States, whether it is the FDA-approved brand or a compounded preparation. Supplements marketed as GLP-1 boosters, "natural Zepbound," or similar are a separate, unregulated consumer category and do not contain tirzepatide. Any legitimate route requires an evaluation by a licensed provider.

No. There is no FDA-approved generic tirzepatide. Zepbound® is still under patent, so no generic exists in the United States. Compounded tirzepatide is not a generic — it is a non-FDA-approved preparation made by a state-licensed US compounding pharmacy under an individual prescription, and it has not been clinically studied as a finished product. Anything advertised as "generic Zepbound" is describing something other than an FDA-approved generic, and it is worth asking the seller exactly what they mean.

Cost depends on the route. Brand Zepbound® runs roughly $1,000–$1,200 a month at retail without insurance, and Lilly's self-pay vials bring that to around $299–$449 a month depending on dose. Compounded tirzepatide through a telehealth provider is typically the lower-cost route — at REMEVi it is $249 your first month, then $379/month, or $269/month on the 52-week plan, all-inclusive with no membership fee. Cheapest is not automatically the right choice: verify the pharmacy is state-licensed, that a licensed provider actually evaluates you, and that the price you are quoted includes the clinical care and shipping.